Delta-Fly Pharma, Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

DFP-10917 · Diabetes
DFP-10917 is a small molecule that targets the SGLT2 receptor.

Phase 1 pipeline

DFP-14927

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Delta-Fly Pharma, Inc. portfolio CI brief
Delta-Fly Pharma, Inc. pipeline updates RSS

Frequently asked questions about Delta-Fly Pharma, Inc.

What is Delta-Fly Pharma, Inc.'s pipeline?

Delta-Fly Pharma, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include DFP-10917.

Sector hub: All tracked pharma companies